Advanced search
Publication Cover
OncoImmunology Volume 12, 2023 - Issue 1
Submit an article Journal homepage
1,003
Views
0
CrossRef citations to date
0
Altmetric
Original Research

A mechanism of IL-34-induced resistance against cytotoxic anti-cancer therapies such as radiation by X-ray and chemotherapy by Oxaliplatin

Nanumi HanDivision of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, JapanView further author information
,
Haruka WadaDivision of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, JapanView further author information
,
Takuto KobayashiDivision of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, JapanView further author information
,
Ryo OtsukaDivision of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, JapanView further author information
&
Ken-Ichiro SeinoDivision of Immunobiology, Institute for Genetic Medicine, Hokkaido University, Sapporo, JapanCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-4122-1718View further author information
ORCID Icon
Article: 2238499 | Received 28 Mar 2023, Accepted 15 Jul 2023, Published online: 24 Jul 2023

References

  • Lin H, Lee E, Hestir K, Leo C, Huang M, Bosch E, Halenbeck R, Wu G, Zhou A, Behrens D, et al. Discovery of a cytokine and its receptor by functional screening of the extracellular proteome. Science. 2008;320(5877):807–9. doi:10.1126/science.1154370.
  • Baghdadi M, Umeyama Y, Hama N, Kobayashi T, Han N, Wada H, Seino KI. Interleukin-34, a comprehensive review. Journal Of Leukocyte Biology query. 2018;104(5):931–951. doi:10.1002/JLB.MR1117-457R.
  • Uhlen M, Zhang C, Lee S, Sjöstedt E, Fagerberg L, Bidkhori G, Benfeitas R, Arif M, Liu Z, Edfors F, et al. A pathology atlas of the human cancer transcriptome. Science. 2017;357(6352). doi:10.1126/science.aan2507.
  • Baghdadi M, Endo H, Takano A, Ishikawa K, Kameda Y, Wada H, Miyagi Y, Yokose T, Ito H, Nakayama H, et al. High co-expression of IL-34 and M-CSF correlates with tumor progression and poor survival in lung cancers. Sci Rep. 2017;8(1):1–10. doi:10.1038/s41598-017-18796-8. 81. 2018.
  • Zhou S-L, Hu Z-Q, Zhou Z-J, Dai Z, Wang Z, Cao Y, Fan J, Huang X-W, Zhou J. MiR-28-5p-IL-34-macrophage feedback loop modulates hepatocellular carcinoma metastasis. Hepatology. 2016;63(5):1560–1575. doi:10.1002/HEP.28445.
  • Franzè E, Dinallo V, Rizzo A, Di Giovangiulio M, Bevivino G, Stolfi C, Caprioli F, Colantoni A, Ortenzi A, Di Grazia A, et al. Interleukin-34 sustains pro-tumorigenic signals in colon cancer tissue. Oncotarget. 2018;9(3):3432–3445. doi:10.18632/oncotarget.23289.
  • Li CH, Chen ZM, Chen PF, Meng L, Sui WN, Ying SC, Xu AM, Han WX. Interleukin-34 promotes the proliferation and epithelial-mesenchymal transition of gastric cancer cells. World J Gastrointest Oncol. 2022;14(10):1968. doi:10.4251/WJGO.V14.I10.1968.
  • Ségaliny AI, Mohamadi A, Dizier B, Lokajczyk A, Brion R, Lanel R, Amiaud J, Charrier C, Boisson-Vidal C, Heymann D. Interleukin-34 promotes tumor progression and metastatic process in osteosarcoma through induction of angiogenesis and macrophage recruitment. Int J Cancer. 2015;137(1):73–85. doi:10.1002/IJC.29376.
  • Han N, Baghdadi M, Ishikawa K, Endo H, Kobayashi T, Wada H, Imafuku K, Hata H, Seino K. Enhanced IL-34 expression in Nivolumab-resistant metastatic melanoma. Inflamm Regen. 2018;38(1). doi:10.1186/s41232-018-0060-2.
  • Hama N, Kobayashi T, Han N, Yagita H, Baghdadi M, Seino K-I. Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade. 2020; doi:10.1016/j.isci.2020.101584.
  • Lhuillier C, Rudqvist NP, Yamazaki T, Zhang T, Charpentier M, Galluzzi L, Dephoure N, Clement CC, Santambrogio L, Zhou XK, et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest. 2021;131(5). doi:10.1172/JCI138740.
  • Baghdadi M, Wada H, Nakanishi S, Abe H, Han N, Wira EP, Endo D, Watari H, Sakuragi N, Hida Y, et al. Chemotherapy-induced IL34 enhances immunosuppression by tumor-associated macrophages and mediates survival of chemoresistant lung cancer cells. Cancer Res. 2016;76(20):6030–6042. doi:10.1158/0008-5472.CAN-16-1170.
  • Yamazaki T, Hannani D, Poirier-Colame V, Ladoire S, Locher C, Sistigu A, Prada N, Adjemian S, Catani JPP, Freudenberg M, et al. Defective immunogenic cell death of HMGB1-deficient tumors: compensatory therapy with TLR4 agonists. Cell Death Differ. 2014;21(1):69–78. doi:10.1038/CDD.2013.72.
  • Mirlekar B, Pylayeva-Gupta Y. IL-12 family cytokines in cancer and immunotherapy. Cancers Basel. 2021;13(2):1–23. doi:10.3390/CANCERS13020167.
  • Gou HF, Huang J, Shi HS, Chen XC, Wang YS, Mattei F. Chemo-immunotherapy with Oxaliplatin and interleukin-7 inhibits colon cancer metastasis in mice. PLoS One. 2014;9(1):e85789. doi:10.1371/JOURNAL.PONE.0085789.
  • Jang GY, Won LJ, Kim YS, Lee SE, Han HD, Hong KJ, Kang TH, Park YM. Interactions between tumor-derived proteins and Toll-like receptors. Experimental & Molecular Medicine. 2020;52(12):1926–1935. 5212. 2020. doi:10.1038/s12276-020-00540-4.
  • Nakajima S, Mimura K, Kaneta A, Saito K, Katagata M, Okayama H, Saito M, Saze Z, Watanabe Y, Hanayama H, et al. Radiation-induced remodeling of the tumor microenvironment through tumor cell-intrinsic expression of Cgas-STING in esophageal squamous cell carcinoma. Int J Radiat Oncol. 2022 Nov 8;115(4):957–971. doi:10.1016/J.IJROBP.2022.10.028.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.